GYN

UTERINE

  • GOG 0238 – A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients with Pelvic Only Recurrence of Carcinoma of the Uterine Corpus
  • GOG 0275– A Randomized Phase III Study of Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
  • GOG 0277- A Randomized Phase III Study of  Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
  • NRG-GY006– A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

ENDOMETRIAL

  • GOG 0286B– A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy forMeasurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer (Temporarily closed to accrual)
  • GOG 0283– A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, Endometrial, or Endometriosis-Associated Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression

CERVIX

  • GOG 0263 – Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
  • RTOG 0724– A Randomized Phase III Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
  • GOG 0274A Randomized Phase III Study of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
  • NRG-GY006– A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

OVARIAN/FALLOPIAN TUBE

  • GOG 0213– A Randomized Phase III Study of Carboplatin and Paclitaxel (or Gemcitabine) with/or without Bevacizumab followed by Bevacizumab and Secondary Cytoreductuve Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary, and Fallopian Tube Cancer
  • GOG 0264– A Randomized Phase II  Study of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex-Cord Stromal Tumors of the Ovary
  • GOG 0281- A Randomized Phase II/III Study to Assess the Efficacy of Trametinib in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Primary Peritoneal Cancer (Temporarily closed due to drug supply issues)
  • NRG-GY001– A Randomized Phase II Trial of Cabozantinib (XL-184) (NSC#761968) in Women with Recurrent Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum (Temporarily closed to accrual)
  • NRG-GY003– A Randomized Phase II Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (Temporarily closed)
  • GOG 0225– Can Diet and Exercise Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival
  • GOG 0283– A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, Endometrial, or Endometriosis-Associated Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression
  • NRG-GY004- A Phase III study comparing single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in women with Recurrent Platinum-sensitive Ovarian, Fallopian tube, or Primary Peritoneal Cancer
  • NRG-GY005– A Randomized Phase II/III study of the Combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Vulvar

  • GOG 0270– Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) II: An Observational Study

Metastatic

  • RTOG 0631– A Randomized Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis